Shandong Jincheng Pharmaceutical Group Co., Ltd
300233.SZ · SHZ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | CN¥572 | CN¥638 | CN¥722 | CN¥858 |
| % Growth | -10.4% | -11.6% | -15.9% | – |
| Cost of Goods Sold | CN¥363 | CN¥394 | CN¥475 | CN¥514 |
| Gross Profit | CN¥208 | CN¥245 | CN¥247 | CN¥344 |
| % Margin | 36.5% | 38.3% | 34.2% | 40.1% |
| R&D Expenses | CN¥38 | CN¥41 | CN¥33 | CN¥48 |
| G&A Expenses | CN¥0 | -CN¥58 | CN¥90 | CN¥62 |
| SG&A Expenses | CN¥166 | CN¥3 | CN¥165 | CN¥169 |
| Sales & Mktg Exp. | CN¥0 | CN¥61 | CN¥75 | CN¥107 |
| Other Operating Expenses | CN¥19 | CN¥189 | -CN¥1 | CN¥375 |
| Operating Expenses | CN¥223 | CN¥233 | CN¥197 | CN¥272 |
| Operating Income | -CN¥14 | CN¥12 | CN¥50 | CN¥72 |
| % Margin | -2.5% | 1.9% | 6.9% | 8.4% |
| Other Income/Exp. Net | CN¥5 | -CN¥2 | -CN¥0 | -CN¥0 |
| Pre-Tax Income | -CN¥9 | CN¥10 | CN¥50 | CN¥72 |
| Tax Expense | CN¥2 | CN¥1 | CN¥14 | CN¥26 |
| Net Income | -CN¥12 | CN¥8 | CN¥35 | CN¥46 |
| % Margin | -2.1% | 1.3% | 4.9% | 5.3% |
| EPS | -0.031 | 0.021 | 0.09 | 0.12 |
| % Growth | -245.3% | -76.2% | -25% | – |
| EPS Diluted | -0.031 | 0.021 | 0.09 | 0.12 |
| Weighted Avg Shares Out | 379 | 389 | 389 | 379 |
| Weighted Avg Shares Out Dil | 379 | 389 | 389 | 379 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥2 | CN¥2 | CN¥3 | CN¥2 |
| Interest Expense | CN¥2 | CN¥3 | CN¥3 | CN¥4 |
| Depreciation & Amortization | CN¥0 | CN¥78 | CN¥79 | CN¥80 |
| EBITDA | -CN¥6 | CN¥13 | CN¥53 | CN¥155 |
| % Margin | -1.1% | 2% | 7.4% | 18.1% |